M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)
Clinical trial NCT03631706 · COMPLETED
Trial details
- NCT number
- NCT03631706
- Sponsor
- EMD Serono Research & Development Institute, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-01
- Primary completion
- 2021-06-07
- Enrollment
- 304
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.